823 Biomarker Approaches for Anti-Pd-1 in Melanoma: A Meta-Analysis

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.899
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Blood Monocyte Frequency May Be a Biomarker for Response to Anti–PD-1

Cancer Discovery
Oncology
2018English

ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-Pd-1/Pd-L1 Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

Integrated Molecular and Immunophenotypic Analysis of NK Cells in Anti-Pd-1 Treated Metastatic Melanoma Patients

OncoImmunology
OncologyAllergyImmunology
2018English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy